Research Article
Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas
Table 1
The clinical, pathological details and tumor characteristics on CT in Xp11.2 RCC and PRCC (including type 1 and type 2).
| | | Xp11.2 RCC
( = 25) | PRCC
( = 39) | Type 1
( = 15) | Type 2
( = 24) | Xp11.2 versus PRCC | Xp11.2 versus type 1 | Xp11.2 versus type 2 | Type 1 versus type 2 |
| | Gender (male/female) | 9/16 | 28/11 | 12/3 | 16/8 | 0.005 | 0.007 | 0.032 | 0.368 | | Age range (years) | 19~51 | 32~78 | 35~78 | 32~73 | — | — | — | — | | Mean age (years) | 30.7 ± 8.7 | 54.8 ± 11.1 | 55.9 ± 12.2 | 54.2 ± 10.5 | <0.001 | <0.001 | <0.001 | 0.634 | | Gross hematuria | 12/13 | 7/32 | 2/13 | 5/19 | 0.010 | 0.026 | 0.046 | 0.553 | | Location (left/right) | 7/18 | 23/16 | 8/7 | 15/9 | 0.015 | 0.109 | 0.015 | 0.571 | | Location (cortical/cortical-medullar/medullar) | 1/23/1 | 8/28/3 | 4/11/0 | 4/17/3 | 0.131 | 0.089 | 0.159 | 0.311 | | Diameter (cm) | 5.4 ± 2.2 | 5.0 ± 2.4 | 3.6 ± 1.6 | 5.8 ± 2.5 | 0.426 | 0.009 | 0.592 | 0.002 | | Boundary (clear/unclear) | 21/4 | 25/14 | 13/2 | 12/12 | 0.084 | 0.819 | 0.011 | 0.020 | | Shape (regular/irregular) | 14/11 | 25/14 | 12/3 | 13/11 | 0.517 | 0.123 | 1.000 | 0.102 | | Attenuation (homo-/heterogeneous) | 5/20 | 20/19 | 12/3 | 8/16 | 0.012 | <0.001 | 0.291 | 0.005 | | Nature (solid/cystic-solid/cystic) | 2/22/1 | 30/9/0 | 15/0/0 | 15/9/0 | <0.001 | <0.001 | <0.001 | 0.007 | | Hemorrhage (with/without) | 10/15 | 9/30 | 3/12 | 6/18 | 0.148 | 0.191 | 0.263 | 0.718 | | Circular calcification (with/without) | 10/15 | 6/33 | 1/14 | 5/19 | 0.027 | 0.022 | 0.146 | 0.233 | | Fat (with/without) | 0/25 | 0/39 | 0/15 | 0/24 | 1.000 | 1.000 | 1.000 | 1.000 | | Tumor thrombosis (with/without) | 3/22 | 1/38 | 0/15 | 1/23 | 0.128 | 0.163 | 0.317 | 0.423 | | Lymph node metastasis (with/without) | 3/22 | 4/35 | 0/15 | 4/20 | 0.827 | 0.163 | 0.641 | 0.095 | | Distant metastasis (with/without) | 2/23 | 1/38 | 0/15 | 1/23 | 0.315 | 0.261 | 0.576 | 0.357 | | Treatment (OR/OP/LR/LP/RA) | 6/0/12/7/0 | 7/7/8/16/1 | 0/4/3/7/1 | 7/3/5/9/0 | 0.044 | 0.005 | 0.103 | 0.126 | | Stage (I/II/III/IV) | 17/2/5/1 | 27/7/3/2 | 14/1/0/0 | 13/6/3/2 | 0.397 | 0.222 | 0.341 | 0.075 | | Median follow-up time (months) | 31 | 32 | 35 | 30 | — | — | — | — | | Survival rate | 88% | 97.4% | 100% | 95.8% | 0.128 | 0.163 | 0.317 | 0.423 |
|
|
Note: Xp11.2 RCC: renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions; PRCC: papillary renal cell carcinoma; OR: open radical nephrectomy; OP: open partial nephrectomy; LR: laparoscopic radical nephrectomy; LP: laparoscopic partial nephrectomy; RA: radiofrequency ablation. .
|
